Modifying the Organ Matrix Pre-engraftment

A New Transplant Paradigm?

Jordan R. Yaron, Jacek M. Kwiecien, Liqiang Zhang, Sriram Ambadapadi, Dara N. Wakefield, William L. Clapp, Wojciech Dabrowski, Michelle Burgin, Barbara H. Munk, Douglas McFadden, Hao Chen, Alexandra R. Lucas

Research output: Contribution to journalReview article

Abstract

The availability of solid organs for transplantation remains low and there is a substantial need for methods to preserve the viability of grafted tissues. Suppression of solid-organ transplant rejection has traditionally focused on highly effective T cell inhibitors that block host immune lymphocyte responses. However, persistent and destructive innate and acquired immune reactions remain difficult to treat, causing late graft loss. Pretreatment of grafts to reduce organ rejection provides an alternate strategy. Approaches using antithrombotics, stem cells, genetic modifications, modulation of infrastructural components (connective tissue, CT; glycocalyx) of donor organs, and engineering of new organs are under investigation. We discuss here new approaches to modify transplanted organs prior to engraftment as a method to reduce rejection, focusing on the CT matrix.

Original languageEnglish (US)
JournalTrends in Molecular Medicine
DOIs
StatePublished - Jan 1 2019

Fingerprint

Transplants
Glycocalyx
Tissue Survival
Graft Rejection
Organ Transplantation
Connective Tissue
Stem Cells
Tissue Donors
Lymphocytes
T-Lymphocytes

Keywords

  • carbohydrate
  • connective tissue
  • donor
  • glycosaminoglycans
  • rejection
  • transplant

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology

Cite this

Yaron, J. R., Kwiecien, J. M., Zhang, L., Ambadapadi, S., Wakefield, D. N., Clapp, W. L., ... Lucas, A. R. (2019). Modifying the Organ Matrix Pre-engraftment: A New Transplant Paradigm? Trends in Molecular Medicine. https://doi.org/10.1016/j.molmed.2019.04.002

Modifying the Organ Matrix Pre-engraftment : A New Transplant Paradigm? / Yaron, Jordan R.; Kwiecien, Jacek M.; Zhang, Liqiang; Ambadapadi, Sriram; Wakefield, Dara N.; Clapp, William L.; Dabrowski, Wojciech; Burgin, Michelle; Munk, Barbara H.; McFadden, Douglas; Chen, Hao; Lucas, Alexandra R.

In: Trends in Molecular Medicine, 01.01.2019.

Research output: Contribution to journalReview article

Yaron, JR, Kwiecien, JM, Zhang, L, Ambadapadi, S, Wakefield, DN, Clapp, WL, Dabrowski, W, Burgin, M, Munk, BH, McFadden, D, Chen, H & Lucas, AR 2019, 'Modifying the Organ Matrix Pre-engraftment: A New Transplant Paradigm?', Trends in Molecular Medicine. https://doi.org/10.1016/j.molmed.2019.04.002
Yaron, Jordan R. ; Kwiecien, Jacek M. ; Zhang, Liqiang ; Ambadapadi, Sriram ; Wakefield, Dara N. ; Clapp, William L. ; Dabrowski, Wojciech ; Burgin, Michelle ; Munk, Barbara H. ; McFadden, Douglas ; Chen, Hao ; Lucas, Alexandra R. / Modifying the Organ Matrix Pre-engraftment : A New Transplant Paradigm?. In: Trends in Molecular Medicine. 2019.
@article{a6037f458f6c40bf9ecbbd5fbb2746f9,
title = "Modifying the Organ Matrix Pre-engraftment: A New Transplant Paradigm?",
abstract = "The availability of solid organs for transplantation remains low and there is a substantial need for methods to preserve the viability of grafted tissues. Suppression of solid-organ transplant rejection has traditionally focused on highly effective T cell inhibitors that block host immune lymphocyte responses. However, persistent and destructive innate and acquired immune reactions remain difficult to treat, causing late graft loss. Pretreatment of grafts to reduce organ rejection provides an alternate strategy. Approaches using antithrombotics, stem cells, genetic modifications, modulation of infrastructural components (connective tissue, CT; glycocalyx) of donor organs, and engineering of new organs are under investigation. We discuss here new approaches to modify transplanted organs prior to engraftment as a method to reduce rejection, focusing on the CT matrix.",
keywords = "carbohydrate, connective tissue, donor, glycosaminoglycans, rejection, transplant",
author = "Yaron, {Jordan R.} and Kwiecien, {Jacek M.} and Liqiang Zhang and Sriram Ambadapadi and Wakefield, {Dara N.} and Clapp, {William L.} and Wojciech Dabrowski and Michelle Burgin and Munk, {Barbara H.} and Douglas McFadden and Hao Chen and Lucas, {Alexandra R.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.molmed.2019.04.002",
language = "English (US)",
journal = "Trends in Molecular Medicine",
issn = "1471-4914",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Modifying the Organ Matrix Pre-engraftment

T2 - A New Transplant Paradigm?

AU - Yaron, Jordan R.

AU - Kwiecien, Jacek M.

AU - Zhang, Liqiang

AU - Ambadapadi, Sriram

AU - Wakefield, Dara N.

AU - Clapp, William L.

AU - Dabrowski, Wojciech

AU - Burgin, Michelle

AU - Munk, Barbara H.

AU - McFadden, Douglas

AU - Chen, Hao

AU - Lucas, Alexandra R.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The availability of solid organs for transplantation remains low and there is a substantial need for methods to preserve the viability of grafted tissues. Suppression of solid-organ transplant rejection has traditionally focused on highly effective T cell inhibitors that block host immune lymphocyte responses. However, persistent and destructive innate and acquired immune reactions remain difficult to treat, causing late graft loss. Pretreatment of grafts to reduce organ rejection provides an alternate strategy. Approaches using antithrombotics, stem cells, genetic modifications, modulation of infrastructural components (connective tissue, CT; glycocalyx) of donor organs, and engineering of new organs are under investigation. We discuss here new approaches to modify transplanted organs prior to engraftment as a method to reduce rejection, focusing on the CT matrix.

AB - The availability of solid organs for transplantation remains low and there is a substantial need for methods to preserve the viability of grafted tissues. Suppression of solid-organ transplant rejection has traditionally focused on highly effective T cell inhibitors that block host immune lymphocyte responses. However, persistent and destructive innate and acquired immune reactions remain difficult to treat, causing late graft loss. Pretreatment of grafts to reduce organ rejection provides an alternate strategy. Approaches using antithrombotics, stem cells, genetic modifications, modulation of infrastructural components (connective tissue, CT; glycocalyx) of donor organs, and engineering of new organs are under investigation. We discuss here new approaches to modify transplanted organs prior to engraftment as a method to reduce rejection, focusing on the CT matrix.

KW - carbohydrate

KW - connective tissue

KW - donor

KW - glycosaminoglycans

KW - rejection

KW - transplant

UR - http://www.scopus.com/inward/record.url?scp=85065762371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065762371&partnerID=8YFLogxK

U2 - 10.1016/j.molmed.2019.04.002

DO - 10.1016/j.molmed.2019.04.002

M3 - Review article

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

SN - 1471-4914

ER -